This article considers the problems associated with intensive glycaemic control in children and adolescents and how these may be circumvented. Use of insulin analogues, alternative insulin delivery methodologies and implementation of education programmes and other adjunctive strategies are discussed.
Karvonen M., Viik-Kajander M., Moltchanova E. et al. Incidence of Childhood Type 1 Diabetes Worldwide. Diabetes Care2000;23:1516-26.
2.
Gale EAThe rise of childhood type 1 diabetes in the 20th century. Diabetes2002;51:3353-61.
3.
Edge J., Ford-Adams M., Dunger D.Causes of death in children with insulin-dependent diabetes 1990-96 . Arch Dis Child1999;81:318-23.
4.
Mortensen HB , Hougaard P.Comparison of metabolic control in a cross-sectional study of 2,873 children and adolescents with IDDM from 18 countries. The Hvidore Study Group on Childhood Diabetes. Diabetes Care1997;20:714-20.
5.
Holl RW, Swift PG, Mortensen HB et al. Insulin injection regimens and metabolic control in an international survey of adolescents with type 1 diabetes over 3 years: results from the Hvidore study group. Eur J Paediatr2003;162:22-9.
6.
Olsen BS, Johannesen J., Sjolie AK et al. Metabolic control and prevalence of microvascular complications in young Danish Patients with Type 1 diabetes mellitus. Diabetic Med2003;16:79-85.
7.
Diabetes Control and Complications Trial Research Group.Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Paediatr1994;125: 177-88.
8.
Tattersall R. , Lowe J.Diabetes in adolescence. Diabetologia1981;20:51723.
9.
Acerini CL, Williams RM, Dunger DBMetabolic impact of puberty on the course of type 1 diabetes. Diabetes Metab2001;4:S19-S25.
10.
Schultz CJ, Konopelska Bahu T., Dalton RN et al. Microalbuminuria prevalence varies with age, sex and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care1999;22:495-502.
11.
Department of Health.National Service Framework for Diabetes: Standards. London: Stationery Office, 2001.
12.
Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med1993;329:977-86.
13.
Amin R., Ross K., Acerini CL et al. Hypoglycaemia prevalence in pre-pubertal children with Type 1 diabetes on standard insulin regimen: use of continuous glucose monitoring system. Diabetes Care2003;26:662-7.
14.
Bjorgaas M. , Gimse R., Vik T., Sand T.Cognitive function in type 1 diabetes children with and without episodes of severe hypoglycaemia . Acta Paediatr1997;86:148-53.
15.
Bryden KS, Peveler RC, Stein A. et al. Clinical and psychological course of diabetes from adolescence to young adulthood: a longitudinal cohort study. Diabetes Care2001;24:1536-40.
16.
Bryden KS, Dunger DB, Mayou RA, Peveler RC, Neil HAPoor prognosis of young adults with type 1 diabetes: a longitudinal study . Diabetes Care2003;26:1052-7.
Ahmed B., Levy J.Pharmacology of insulin. Br J Diabetes Vasc Dis2004;4: 10-14.
19.
Tamborlane WV, Bonfig W., Boland E.Recent advances in treatment of youth with Type 1 diabetes: better care through technology. Diabetic Med2001;18:864-70.
20.
Danne T., Aman J., Schober E. et al. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care2003;26:2359-64.
21.
Mohn A., Strang S., Wernicke-Panten K. et al. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Diabetes Care2000 ;23:557-9.
22.
Mohn A., Ross KM, Matyka KA et al. Lispro or regular insulin for multiple injection therapy in adolescence. Diabetes Care1999;22:27-32.
23.
Ford-Adams ME, Murphy NP, Moore EJ et al. Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus . Diabetic Med2003;20:656-60.
24.
Deeb LC, Holcombe JH, Brunelle R. et al. Insulin lispro lowers postprandial glucose in prepubertal children with diabetes. Pediatrics2001;108: 1175-9.
25.
Lepore M., Pampanelli S., Fanelli C. et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes2000;49:2142-8.
26.
Bolli GB, Di Marchi RD, Park GD, Pramming S., Koivisto VAInsulin analogues and their potential in the management of diabetes mellitus . Diabetologia1999;42:1151-67.
27.
Dunger D.Will the use of insulin analogs improve glycemic control during adolescence?Paediatric Diabetes2003;4:61-3.
28.
Murphy N., Keane S., Ong K. et al. Randomized Cross-Over Trial of Insulin Glargine Plus Lispro or NPH Insulin Plus Regular Human Insulin in Adolescents With Type 1 Diabetes on Intensive Insulin Regimens. Diabetes Care2003;26:799-804.
29.
Schober E., Schoenle E., Van Dyk J., Wernicke-Panten K., Pediatric Study Group of Insulin Glargine.Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab2002;15:369-76.
30.
Kordonouri O. , Deiss D., Hopfen-Mueller W. et al. Treatment with Insulin Glargine (Lantus®) Reduces Asymptomatic Nightly Hypoglycaemia Detected by Continuous Subcutaneous Glucose Monitoring (CGMS) in Children and Adolescents with Type 1 Diabetes (dm). Diabetes2002;51: Abstract 1754P.
31.
Ratner RE, Hirsch IB, Neifing JL et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care2000;23:639-43.
32.
Raskin P., Klaff L., Bergenstal R. et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care2000; 23:1666-71.
33.
Ashwell S., Bilous R., Heller S., Hepburn D., Home P.Improvement in overall blood glucose control with insulin glargine plus insulin lispro in comparison with NPH insulin plus unmodified human insulin in people with type 1 diabetes. Diabetologia2003;46(suppl 2):A784.
34.
Danne T., Lupke K., Walte K., Von Schetz W., Gall MAInsulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care2003;26:3087-92.
35.
Vague P., Selam JL, Skeie S. et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care2003;26:5R90-6.
36.
Ahern JAH , Boland EA, Doane R. et al. Insulin pump therapy in paediatrics: a therapeutic alternative to safely lower HbA1C levels across all age groups . Pediatr Diabetes2002;3:10-15.
37.
Boland E., Brandt C., Monsod T. et al. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care2001;24:1858-62.
38.
Maniatis AK , Klingensmith GJ, Slover RH, Mowry CJ, Chase HPContinuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics2003;107:351-6.
39.
Willi SM, Planton J., Egede L., Schwarz S.Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr2003; 143:796-801.
40.
Renard E., Costalat G., Bringer J.From external to implantable insulin pump, can we close the loop?Diabetes Metab2002;28:2S19-2S25.
41.
Selam JLExternal and implantable insulin pumps: current place in the treatment of diabetes. Exp Clin Endocrinol Diabetes2001 ;109(suppl 2): S333-S340.
42.
Skyler JS, Cefalu WT, Kourides IA et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomized proof of concept study. Lancet2001;357:331-5.
43.
Royle P., Waugh N., McAuley L., McIntyre L., Thomas S.Inhaled insulin in diabetes mellitus. Cochrane Database Syst Rev2003;3:CD003890.
44.
DAFNE Study Group.Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ2002; 325:746.
45.
Hamilton J. , Cummings E., Zdravkovic V., Finegood D., Daneman D.Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial . Diabetes Care2003;26: 138-43.
46.
Sarnblad S. , Kroon M., Aman J.Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebocontrolled trial with aspects on insulin sensitivity. Eur J Endocrinol2003; 149:323-9.
47.
Acerini CL, Patton CM, Savage MO et al. Randomised placebo-controlled trial of human recombinant insulin-like growth factor-I plus intensive insulin-therapy in adolescents with insulin-dependent diabetes mellitus. Lancet1997;350:1199-204.
